VERTEX PHARMACEUTICALS INC / MA — Form 10-Q

Vertex Pharmaceuticals executed a new $500 million revolving credit facility dated July 30, 2026, with Bank of America as administrative agent and a syndicate of major banks (BNP Paribas, Citibank, JPMorgan, Morgan Stanley, Wells Fargo) as co-arrangers. The facility matures July 30, 2031 (5-year term). Designated foreign borrowers include Vertex Europe and Vertex Ireland. The facility replaces the prior July 2022 credit agreement and includes standard revolving credit terms with commitments up to $500M, letters of credit up to $100M sublimit, and swingline loans up to $20M sublimit.